April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Decreased Amyloid Beta Antigen And Antibody Levels In Age-related Macular Degeneration
Author Affiliations & Notes
  • Jeeyun Ahn
    Department of Ophthalmology, Seoul National University Bundang Hospital, Gyeonggi do, Republic of Korea
  • Se Joon Woo
    Department of Ophthalmology, Seoul National University Bundang Hospital, Gyeonggi do, Republic of Korea
  • Kyu Hyung Park
    Department of Ophthalmology, Seoul National University Bundang Hospital, Gyeonggi do, Republic of Korea
  • Footnotes
    Commercial Relationships  Jeeyun Ahn, None; Se Joon Woo, None; Kyu Hyung Park, None
  • Footnotes
    Support  This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0072603)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2339. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jeeyun Ahn, Se Joon Woo, Kyu Hyung Park; Decreased Amyloid Beta Antigen And Antibody Levels In Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2339.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare amyloid β (Aβ) antigen and antibody levels in the peripheral blood and vitreous fluid of age-related macular degeneration (AMD) patients and normal control groups.

Methods: : The antigen and antibody levels of Aβ (Aβ1-42 and 1-40) were analyzed after age adjustment in the sera of 321 AMD patients and 377 normal controls. Vitreous Aβ antigen and antibody titers were analyzed in the vitreous fluid of 13 AMD patients and 17 normal controls. Aβ antigen and antibody analysis was performed using enzyme-linked immunosorbent assay (ELISA).

Results: : Aβ antibody and antigen levels were decreased in AMD patient serum as well as vitreous fluid. The mean Aβ1-40 antigen titer was 0.30±0.09 and 0.31±0.08 in AMD and control sera, respectively (P = 0.014). The mean Aβ1-42 antigen titer was 0.28±0.07 and 0.29±0.06 in the sera of AMD and control cases, respectively (P = 0.008).The mean anti-Aβ1-40 antibody titer was 0.29±0.06 and 0.32±0.05 in AMD and control sera, respectively (P < 0.0001). The mean anti-Aβ1-42 antibody titer was 0.29±0.06 and 0.31±0.06 in the sera of AMD and control cases, respectively (P < 0.0001). Vitreous Aβ1-40 antigen titer was 0.039±0.003 and 0.046±0.003 in AMD and control cases, respectively (P < 0.001). Vitreous Aβ1-42 antigen titer was 0.045±0.003 and 0.046±0.002 in AMD and control cases, respectively (P = 0.191). Vitreous anti-Aβ1-40 antibody titer was 0.20±0.02 and 0.25±0.02 in AMD and control cases, respectively (P < 0.001). Vitreous anti-Aβ1-42 antibody titer was 0.22±0.02 and 0.25±0.01 in AMD and control cases, respectively (P < 0.001).

Conclusions: : Anti-Aβ antigen and antibody levels were decreased in the sera and vitreous fluid of AMD patients compared to a normal control group. The possible role of Aβ in the pathogenesis of AMD is suggested.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×